Debra Patt, MD, PhD, MBA

Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.

Lawmakers across the country can learn from examples in states like Arkansas and Texas.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, explore how the removal of risk evaluation and management strategies (REMS) for chimeric antigen receptor (CAR) T-cell (CAR T) therapies can improve health equity, expand access in community settings, and elevate the pharmacist’s role in care coordination.

Debra Patt, MD, PhD, MBA; and Houston Holmes, MD, discuss the ramifications of the FDA's removal of REMS requirements for approved chimeric antigen receptor (CAR) T-cell (CAR T) therapies.